Dementia and Alzheimer Disease

H. E. Hinson, MD, MCR, FAAN, discussed how neurology is rapidly evolving toward interventional therapies, prevention-focused care, and adaptive trial designs, based on presentations from AAN 2026.

Kristine Yaffe, MD, distinguished professor at UCSF and SEQUINS Hall of Fame honoree, discusses dementia prevention, modifiable risk factors, and ongoing disparities in brain health and cognitive aging.

Gus Alva, MD, DFAPA, medical director of ATP Clinical Research, commented on the potential clinical impact of AXS-05 for agitation in Alzheimer disease, caregiver burden, and the evolving collaboration between neurology and psychiatry.

As a 2026 SEQUINS Hall of Fame honoree, James Galvin, MD, MPH, reflected on advancing equitable dementia care, culturally relevant cognitive assessment, and improving brain health outcomes across diverse communities.

As a 2026 SEQUINS Hall of Fame honoree, George Howard, DrPH, commented on decades of stroke disparities research, the impact of the REGARDS study, and why future efforts must focus more directly on upstream risk factors.

Kinan Muhammed, MD, PhD, consultant neurologist and co-founder and Chief Medical Officer for Kneu Health, discussed how smartphone-based remote monitoring tools may help clinicians track motor and cognitive changes in Parkinson disease and dementia more continuously.

As a 2026 SEQUINS Hall of Fame honoree, Gretchen L. Birbeck, MD, MPH, reflected on her decades-long work advancing equity in global neurologic care and improving epilepsy outcomes in resource-limited settings.

As a 2026 SEQUINS Hall of Fame honoree, Edwin Trevathan, MD, MPH, reflects on global pediatric neurology, community-based care delivery, and the ongoing effort to reduce neurologic health inequities worldwide.

The FDA extended review of Eisai and Biogen’s supplemental filing for once-weekly subcutaneous lecanemab initiation in early Alzheimer disease, with a new decision date set for August 2026 amid ongoing evaluation of additional submitted data.

Adam Vogel, PhD, Professor of Speech Neuroscience at The University of Melbourne and Chief Science Officer at Redenlab, discusses the emerging role of speech analytics as an objective, scalable biomarker in neurodegenerative disease research.

David Setboun, PharmD, MBA, CEO of PharmatrophiX, and Frank Longo, MD, PhD, Co-founder & Chairman, discuss LM11A-31’s upstream mechanism targeting p75 signaling and its potential to modify neurodegenerative disease biology.

Single-patient study reports reductions in Alzheimer-related biomarkers following dapsone-based therapy for chronic Lyme disease, highlighting a potential but unproven infection–neurodegeneration link.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 1, 2026.

FDA clears AXS-05 to ease Alzheimer dementia agitation, offering an oral option that significantly delays symptom relapse in long-term data.

Findings from the phase 2 ADDRESS-LC trial, assessing BioVie’s bezisterim in patients with long COVID–related fatigue and cognitive impairment, are anticipated to be reported in the first half of 2026.

Jaime Ramos, PhD, Assistant Professor of Psychiatry and Neurology at NYU Grossman School of Medicine, discussed the role of neutrophil-to-lymphocyte ratio as a scalable inflammatory marker associated with future dementia risk.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 24, 2026.

A living systematic review presented at AAN 2026 showed that GLP-1 receptor agonists demonstrated biomarker and real-world signals of neuroprotection in Alzheimer disease.

Erika Trovato, DO, MS, associate chief medical officer at Burke Rehabilitation Hospital in New York, discusses interdisciplinary rehabilitation, emerging technologies, and the evolving focus on long-term outcomes and caregiver support in brain injury care.

A data-driven slideshow for National Public Health Week highlights the global burden of neurologic diseases, featuring key statistics on prevalence, disability, and workforce gaps across major conditions.

Lead Investigators explain blood-based “Clock Model” that uses plasma p-tau217 levels to estimate when symptoms of Alzheimer disease may begin, with an average prediction error of approximately 3 to 4 years.

In recognition of National Public Health Week, held April 6-12, NeurologyLive summarizes recent literature showing that environmental exposures are associated with increased risk of neurologic disorders.

High-dose influenza vaccination was associated with a lower risk of incident Alzheimer dementia compared with standard-dose vaccination among adults aged 65 years and older in a large US claims-based cohort study.

Members from Danaher Diagnostics provided clinical commentary and insights on an emerging immunoassay geared towards testing apolipoprotein (APOE) in patients with suspected Alzheimer disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 3, 2026.